Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Biotechnology - Page 60

Biotechnology

Amyris achieved promising in-vivo results for intranasal delivery of RNA/NLC vaccine
Biotechnology | COVID-19 | Non-Profit Research | Vaccine

Amyris achieved promising in-vivo results for intranasal delivery of RNA/NLC vaccine

On Aug. 20, 2021, Amyris announced promising in-vivo results in a study of its licensed RNA vaccine through…

Read More Amyris achieved promising in-vivo results for intranasal delivery of RNA/NLC vaccineContinue

Vaccines still effective against Delta variant of concern, says Oxford-led study of the COVID-19 Infections Survey
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine

Vaccines still effective against Delta variant of concern, says Oxford-led study of the COVID-19 Infections Survey

On Aug. 19, 2021, the University of Oxford reported that obtaining two vaccine doses remained the most effective…

Read More Vaccines still effective against Delta variant of concern, says Oxford-led study of the COVID-19 Infections SurveyContinue

Moderna announced supply agreement with Canada for expanded supply of COVID-19 Vaccine from 2022 – 2024
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced supply agreement with Canada for expanded supply of COVID-19 Vaccine from 2022 – 2024

On Aug. 16, 2021, Moderna announced a revised supply agreement with the Government of Canada for up to…

Read More Moderna announced supply agreement with Canada for expanded supply of COVID-19 Vaccine from 2022 – 2024Continue

FDA approved Merck’s hypoxia-inducible factor-2 alpha inhibitor WELIREG (belzutifan)
Biotechnology | FDA | Neurology | Oncology | Therapeutics

FDA approved Merck’s hypoxia-inducible factor-2 alpha inhibitor WELIREG (belzutifan)

On Aug. 13, 2021, Merck announced that the U.S. Food and Drug Administration (FDA) had approved WELIREG, an…

Read More FDA approved Merck’s hypoxia-inducible factor-2 alpha inhibitor WELIREG (belzutifan)Continue

Moderna announced FDA authorization of third dose of COVID-19 vaccine for immunocompromised individuals
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

Moderna announced FDA authorization of third dose of COVID-19 vaccine for immunocompromised individuals

On Aug. 13, 2021, Moderna announced that the Food and Drug Administration (FDA) had approved an update to…

Read More Moderna announced FDA authorization of third dose of COVID-19 vaccine for immunocompromised individualsContinue

The Department of Veterans Affairs expanded mandate for COVID-19 vaccines among VHA employees
Biotechnology | COVID-19 | Infectious Disease | Vaccine

The Department of Veterans Affairs expanded mandate for COVID-19 vaccines among VHA employees

On Aug. 12, 2021, the U.S. Department of Veterans Affairs (VA) announced that it expanded his previous COVID-19…

Read More The Department of Veterans Affairs expanded mandate for COVID-19 vaccines among VHA employeesContinue

Moderna announced study showing Its COVID-19 vaccine maintained antibodies against variants of concern
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced study showing Its COVID-19 vaccine maintained antibodies against variants of concern

On Aug. 12, 2021, Moderna announced the publication of new data on the durability of the Moderna COVID-19…

Read More Moderna announced study showing Its COVID-19 vaccine maintained antibodies against variants of concernContinue

Innovation Pharmaceuticals’ phase 2 clinical trial of Brilacidin for COVID-19 trial database under review in preparation for lock
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics

Innovation Pharmaceuticals’ phase 2 clinical trial of Brilacidin for COVID-19 trial database under review in preparation for lock

On Aug. 12, 2021, Innovation Pharma released information regarding the status of its randomized, double-blind, placebo-controlled Phase 2…

Read More Innovation Pharmaceuticals’ phase 2 clinical trial of Brilacidin for COVID-19 trial database under review in preparation for lockContinue

NIH launched study of third COVID-19 vaccine dose in kidney transplant recipients
Biotechnology | COVID-19 | Infectious Disease | Life Science History | NIH | Vaccine

NIH launched study of third COVID-19 vaccine dose in kidney transplant recipients

On Aug. 10, 2021, the National Institutes of Health (NIH) announced that a pilot study had begun to…

Read More NIH launched study of third COVID-19 vaccine dose in kidney transplant recipientsContinue

Moderna and Canada announced collaboration to bring mRNA manufacturing to Canada
Biotechnology | Infectious Disease | Vaccine

Moderna and Canada announced collaboration to bring mRNA manufacturing to Canada

On Aug. 10, 2021, Moderna announced a Memorandum of Understanding (MoU) with the government of Canada to build…

Read More Moderna and Canada announced collaboration to bring mRNA manufacturing to CanadaContinue

Australian Therapeutic Goods Administration granted provisional registration for Moderna’s COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Australian Therapeutic Goods Administration granted provisional registration for Moderna’s COVID-19 vaccine

On Aug. 9, 2021, Moderna announced that the Therapeutic Goods Administration (TGA) had granted provisional registration to the…

Read More Australian Therapeutic Goods Administration granted provisional registration for Moderna’s COVID-19 vaccineContinue

INOVIO and Advaccine receive regulatory allowance for prime-boost clinical trials in China using INO-4800, COVID-19 DNA vaccine candidate
Biotechnology | COVID-19 | Infectious Disease | Vaccine

INOVIO and Advaccine receive regulatory allowance for prime-boost clinical trials in China using INO-4800, COVID-19 DNA vaccine candidate

On Aug. 9, 2021, Inovio Pharma announced that it had received regulatory allowance for two clinical trials investigating…

Read More INOVIO and Advaccine receive regulatory allowance for prime-boost clinical trials in China using INO-4800, COVID-19 DNA vaccine candidateContinue

BD and CerTest Biotec announced CE Mark for molecular test to detect, identify certain SARS-CoV-2 variants
Biotechnology | Diagnostics

BD and CerTest Biotec announced CE Mark for molecular test to detect, identify certain SARS-CoV-2 variants

On Aug. 6, 2021, BD (Becton, Dickinson) and CerTest Biotec announced the CE mark for a molecular test…

Read More BD and CerTest Biotec announced CE Mark for molecular test to detect, identify certain SARS-CoV-2 variantsContinue

Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibody
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibody

On Aug. 5, 2021, Novavax announced preliminary data demonstrating that a single booster dose of its recombinant nanoparticle…

Read More Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibodyContinue

Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccine

On Aug. 4, 2021, Novavax announced that it had reached an agreement with the European Commission (EC) for…

Read More Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccineContinue

NEJM published positive phase 3 trial results for REGEN-COV to prevent SARS-CoV-2 infection
Biotechnology | COVID-19

NEJM published positive phase 3 trial results for REGEN-COV to prevent SARS-CoV-2 infection

On Aug. 4, 2021, Regeneron announced that the New England Journal of Medicine (NEJM) had published positive detailed…

Read More NEJM published positive phase 3 trial results for REGEN-COV to prevent SARS-CoV-2 infectionContinue

INOVIO dosed first participant in phase 2 trial for its DNA vaccine against MERS, a Coronavirus Disease
Biotechnology | COVID-19 | Vaccine

INOVIO dosed first participant in phase 2 trial for its DNA vaccine against MERS, a Coronavirus Disease

On Aug. 4, 2021, Inovio Pharma announced that the company had dosed the first Phase 2 trial subject…

Read More INOVIO dosed first participant in phase 2 trial for its DNA vaccine against MERS, a Coronavirus DiseaseContinue

CytoDyn received clearance from Brazil’s FDA (ANVISA) to commence pivotal phase 3 trial in critically ill COVID-19 patients
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

CytoDyn received clearance from Brazil’s FDA (ANVISA) to commence pivotal phase 3 trial in critically ill COVID-19 patients

On Aug. 3, 2021, CytoDyn announced that Brazil’s regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved…

Read More CytoDyn received clearance from Brazil’s FDA (ANVISA) to commence pivotal phase 3 trial in critically ill COVID-19 patientsContinue

FDA Approved Expanded BOTOX® Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity
Biotechnology | FDA | Therapeutics

FDA Approved Expanded BOTOX® Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity

On Jul. 29, 2021, BOTOX(R) Allergan, an AbbVie company, announced that the U.S. Food and Drug Administration (FDA)…

Read More FDA Approved Expanded BOTOX® Label to Include Eight New Muscles to Treat Adults with Upper Limb SpasticityContinue

Vaxart reported boosting immune responses in subjects previously vaccinated by a Vaxart vaccine
Biotechnology | Diagnostics | Infectious Disease | Vaccine

Vaxart reported boosting immune responses in subjects previously vaccinated by a Vaxart vaccine

On Jul. 29, 2021, Vaxart announced that it has shown for the first time in clinical trials that…

Read More Vaxart reported boosting immune responses in subjects previously vaccinated by a Vaxart vaccineContinue

SIGA announced collaboration with Oxford University to expanded Access Protocol for Use of TPOXX in Central African Republic
Biotechnology | Therapeutics

SIGA announced collaboration with Oxford University to expanded Access Protocol for Use of TPOXX in Central African Republic

On Jul. 29, 2021, SIGA Technologies announced that it had entered into a collaboration with Oxford University in…

Read More SIGA announced collaboration with Oxford University to expanded Access Protocol for Use of TPOXX in Central African RepublicContinue

Cocrystal’s SARS-CoV-2 3CL protease lead CDI-45205 demonstrated broad-spectrum activity against SARS-CoV-2 Delta and Gamma variants
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

Cocrystal’s SARS-CoV-2 3CL protease lead CDI-45205 demonstrated broad-spectrum activity against SARS-CoV-2 Delta and Gamma variants

On Jul. 29, 2021, Cocrystal Pharma announced that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed…

Read More Cocrystal’s SARS-CoV-2 3CL protease lead CDI-45205 demonstrated broad-spectrum activity against SARS-CoV-2 Delta and Gamma variantsContinue

Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response and protection in preclinical study
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response and protection in preclinical study

On Jul. 28, 2021, GlaxoSmithKline and Vir Biotechnology announced they had signed a Joint Procurement Agreement with the…

Read More Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response and protection in preclinical studyContinue

Oragenics entered into licensing agreement with the NRC of Canada, to pursue next-generation SARS-CoV-2 vaccines
Biotechnology | Infectious Disease | NIH | Vaccine

Oragenics entered into licensing agreement with the NRC of Canada, to pursue next-generation SARS-CoV-2 vaccines

On Jul. 27, 2021, Oragenics announced it had entered into a licensing agreement with the National Research Council…

Read More Oragenics entered into licensing agreement with the NRC of Canada, to pursue next-generation SARS-CoV-2 vaccinesContinue

The COVID-19 Vaccine
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | FDA | Life Science History | Therapeutics | Vaccine

The COVID-19 Vaccine

Cast of Characters: Donald Trump, President | Mike Pence, Vice President | Anthony S. Fauci, MD, Director, National…

Read More The COVID-19 VaccineContinue

COVID-19 vacation Destinations
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine

COVID-19 vacation Destinations

Planning a Summer vacation? Where to go? How about going to one of those large events with tens…

Read More COVID-19 vacation DestinationsContinue

CHMP adopted positive opinion recommending authorization for use of the Moderna COVID-19 vaccine in adolescents in EU
Biotechnology | COVID-19 | Infectious Disease | Vaccine

CHMP adopted positive opinion recommending authorization for use of the Moderna COVID-19 vaccine in adolescents in EU

On Jul. 23, 2021, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…

Read More CHMP adopted positive opinion recommending authorization for use of the Moderna COVID-19 vaccine in adolescents in EUContinue

Moderna announced agreement with Taiwan for 20 million doses of Moderna’s COVID-19 Vaccine and variant booster
Biotechnology | COVID-19 | Infectious Disease | Life Science History | Therapeutics | Vaccine

Moderna announced agreement with Taiwan for 20 million doses of Moderna’s COVID-19 Vaccine and variant booster

On Jul. 22, 2021, Moderna announced a new supply agreement with Taiwan for 20 million doses of Moderna’s…

Read More Moderna announced agreement with Taiwan for 20 million doses of Moderna’s COVID-19 Vaccine and variant boosterContinue

NIH awarded more than $20 million to international HIV database centers
Biotechnology | HIV | NIH

NIH awarded more than $20 million to international HIV database centers

On Jul. 22, 2021, the National Institutes of Health announced it had renewed grants to seven regional centers…

Read More NIH awarded more than $20 million to international HIV database centersContinue

Moderna partnered with Takeda and Government of Japan to aupply additional 50 million doses of COVID-19 vaccine and variant booster candidate
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna partnered with Takeda and Government of Japan to aupply additional 50 million doses of COVID-19 vaccine and variant booster candidate

On Jul. 20, 2021, Moderna announced that the Ministry of Health, Labour and Welfare of Japan (MHLW) and…

Read More Moderna partnered with Takeda and Government of Japan to aupply additional 50 million doses of COVID-19 vaccine and variant booster candidateContinue

Page navigation

Previous PagePrevious 1 … 58 59 60 61 62 … 169 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cardiovascular
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Clinical Research
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search